13 recruiting. 13 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 13 |
| Phase 1 | 6 | Recruiting 6 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy High-dose inactivated influenza vaccine, Standard-dose inactivated influenza vaccine - Hematologic Malignancy, Influenza | Phase 2 | Recruiting | Sung-Han Kim | 60 | 2026-11-02 | 2026-11-09 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant Belumosudil - Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2025-05-21 | 2026-06-29 |
| Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial Cold-stored platelet concentrate - Hematologic Malignancy | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 50 | 2025-05-16 | 2025-07-31 |
| CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-12-31 | 2024-12-06 |
| Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI) Posaconazole - Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 30 | 2024-11-08 | 2026-01-26 |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine - Graft Versus Host Disease, Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 82 | 2024-07-18 | 2026-01-26 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 30 | 2024-03-06 | 2024-04-10 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 60 | 2023-04-27 | 2025-04-27 |
| Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Pirtobrutinib, Venetoclax - Mantle Cell Lymphoma, Non Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-01-25 | 2026-05-05 |
| Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) Human T Lymphoid Progenitor (HTLP) injection - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2022-02-16 | 2026-08-12 |
Hematologic Neoplasms (13) · Leukemia, Myeloid, Acute (3) · Graft vs Host Disease (2) · Influenza, Human (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm, Residual (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Chromosome 7, monosomy (1) · Chromosome Aberrations (1) · Hemorrhage (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma, Mantle-Cell (1) · Myelodysplastic Syndromes (1) · Neurofibromatosis 1 (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Immune System Diseases (5) · Neoplasms by Histologic Type (4) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Myeloid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bone Marrow Diseases (2) · Infections (2)
fludarabine (4) · Cyclophosphamide (3) · Busulfan (2) · Clofarabine (1) · Injections (1) · Levetiracetam (1) · Melphalan (1) · Methotrexate (1) · Rituximab (1) · Thiotepa (1) · Whole-Body Irradiation (1) · belumosudil (1) · pirtobrutinib (1) · posaconazole (1) · thymoglobulin (1)
Nantes University Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Chinese PLA General Hospital (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · Ottawa Hospital Research Institute (1) · Ruijin Hospital (1) · Shenzhen TargetRx Co., Ltd. (1) · Sung-Han Kim (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University Hospital Tuebingen (1)
China (4) · France (3) · United States (3) · Canada (1) · Germany (1) · South Korea (1)
Alan Tinmouth, MD (1) · Bo Jiang, MD (1) · Doris Ponce, MD (1) · Jianxiang Wang, MD (1) · Johnathan MAck, MD (1) · Margaret MacMillan (1) · Mei Heng, M.D., Ph.D (1) · Preetesh Jain, MD, DM, PhD (1)
2019 (1)